NCCS and Illumina join forces to advance genomics research in rare cancers

SINGAPORE: The National Cancer Centre Singapore (NCCS) has entered into a significant collaboration with Illumina to propel genomics research for rare cancers in the country. This strategic partnership aims to enhance the understanding and treatment of adolescent and young adult (AYA) lymphoma patients within a diverse Asian cohort.

Central to this collaboration is the focus on the genetic profiling of AYA lymphoma, leveraging Illumina’s advanced genome sequencing platforms, including the NovaSeq™ 6000 systems. This technology will be instrumental in exploring the genetic underpinnings of lymphoma, potentially leading to improved diagnosis and treatment options.

“Lymphoma in adolescents and young adults can be challenging to treat,” said Dr Jason Chan, Director of the Cancer Discovery Hub at NCCS, “As a medical oncologist, I look forward to finding new ways to more effectively target the disease to offer our young patients in Asia personalised and targeted therapies to improve survival rates and enhance their quality of life.”

Illumina’s commitment to the partnership underscores their dedication to advancing genomics in cancer research. “We are committed to continuing to support the NCCS to gain important insights to improve patient care and outcomes in these groups,” said Amol Zimur, Head of Medical Affairs at Illumina Asia Pacific.

Mr Zimur highlighted the importance of this research in providing a more tailored approach to lymphoma treatment in Asian populations, where current classification systems have not been extensively studied.

This collaboration marks a promising step forward in the quest to enhance therapeutic strategies for lymphoma in young patients, aligning with the broader goals of precision medicine and personalised healthcare in oncology.

TISG/